SEC Filing Summary: Advanced Polymer Systems, Inc. (10-K)
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 1999, for Advanced Polymer Systems, Inc. (APS). APS develops, manufactures, and sells patented drug delivery systems, primarily its Microsponge(R) technology, for use in ethical dermatology, cosmetic, and personal care products. The company operates through strategic alliances with major corporations (e.g., Johnson & Johnson, Avon, Dermik) to license technology and supply materials. As of February 29, 2000, the company had 83 full-time employees and 20,119,042 shares of common stock outstanding.
Key Financial Metrics
| Metric (in thousands) | 1999 | 1998 |
|---|---|---|
| Total Revenues | $20,405 | $20,621 |
| Product Revenues | $14,624 | $13,637 |
| Royalties, License & R&D Fees | $5,481 | $6,984 |
| Milestone Payments | $300 | $0 |
| Net Income | $2,372 | $2,525 |
| Diluted EPS | $0.12 | $0.12 |
| Working Capital | $9,434 | $4,760 |
| Cash & Equivalents | $3,705 | $4,088 |
| Long-Term Debt | $2,409 | $0 |
Profitability: Gross profit on product revenues was $7,767,000 (53% margin). Operating income was $2,826,000.
Material Changes vs. Prior Period
- Revenue Mix: Total revenue declined slightly (1%) to $20.4 million. Product revenues increased 7% due to new cosmeceutical launches, while Royalties, License, and R&D fees dropped 22% primarily due to lower R&D fees and the discontinuation of a Procter & Gamble baby wipe product.
- Net Income: Net income decreased 6% to $2.37 million. This was driven by a $1.3 million cash settlement of a lawsuit with Large Scale Biology Corp. (LSB Corp.) and a 22% increase in General and Administrative (G&A) expenses due to professional fees related to a resolved proxy contest.
- Liquidity & Debt: Working capital improved significantly to $9.4 million. However, the company incurred new long-term debt of $4.0 million in March 1999 (13.87% interest rate) to refinance maturing obligations. Cash used in operating activities was $647,000, compared to $1.5 million in 1998.
- Receivables: Days sales outstanding increased from 68 days in 1998 to 89 days in 1999, attributed to shipment timing weighted toward the end of the year.
Outlook, Risks, and Contingencies
- Product Pipeline: Key developments include the FDA filing for a 5-Fluorouracil (5-FU) product with Dermik (Q4 1999) and ongoing Phase III trials for a second Retin-A Micro formulation. The company is also developing bioerodible polymers for oral and implantable drug delivery.
- Legal Proceedings: A lawsuit filed in February 2000 by Douglas and Albert Kligman alleges partnership dissolution and seeks damages over $75,000. Management denies liability and expects no material adverse effect. The LSB Corp. lawsuit was settled in 1999 for $1.3 million.
- Market Risks: The company relies heavily on strategic alliances; financial results depend on the success of partner marketing efforts. Approximately 51% of net sales in 1999 were concentrated with seven customers.
- Capital Resources: Management believes existing cash, receivables, and revenue streams are sufficient to meet working capital requirements for the foreseeable future.
Investor Verification Checklist
- Customer Concentration: Verify the stability of relationships with the top seven customers who accounted for 51% of sales.
- Regulatory Approvals: Monitor the status of the NDA for the 5-FU product with Dermik and the second Retin-A Micro formulation, as these are critical for future milestone payments and royalties.
- Debt Servicing: Assess the impact of the new $4 million term loan (13.87% interest) on future cash flows and interest expense.
- Receivables Quality: Investigate the cause of the increase in days sales outstanding (68 to 89 days) to ensure it is not indicative of collection issues.
- Legal Exposure: Track the progress of the Kligman lawsuit filed in early 2000.